

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6722023

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
UCB BIOPHARMA SPRL	03/10/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	UCB BIOPHARMA SPRL
<b>Street Address:</b>	ALLÉE DE LA RECHERCHE 60
<b>City:</b>	BRUSSELS
<b>State/Country:</b>	BELGIUM
<b>Postal Code:</b>	1070
<b>Name:</b>	SANOFI
<b>Street Address:</b>	54 RUE LA BOÉTIE
<b>City:</b>	PARIS
<b>State/Country:</b>	FRANCE
<b>Postal Code:</b>	F-75008
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17325036
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(703)712-8525
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(703) 712-8531
<b>Email:</b>	admin@medlerferro.com, docketing@medlerferro.com
<b>Correspondent Name:</b>	MEDLER FERRO WOODHOUSE & MILLS PLLC
<b>Address Line 1:</b>	8201 GREENSBORO DRIVE
<b>Address Line 2:</b>	SUITE 1060
<b>Address Line 4:</b>	MCLEAN, VIRGINIA 22102
<b>ATTORNEY DOCKET NUMBER:</b>	1089-0006US2
<b>NAME OF SUBMITTER:</b>	CYNTHIA M. BOUCHEZ
<b>SIGNATURE:</b>	/Cynthia M. Bouchez/
<b>DATE SIGNED:</b>	05/21/2021

**Total Attachments: 3**

source=1089-0006US2 - Assignment - UCB Biopharma SPRL to UCB Biopharma SPRL and SANOFI#page1.tif

source=1089-0006US2 - Assignment - UCB Biopharma SPRL to UCB Biopharma SPRL and SANOFI#page2.tif

source=1089-0006US2 - Assignment - UCB Biopharma SPRL to UCB Biopharma SPRL and SANOFI#page3.tif

## CONFIRMATORY PATENT ASSIGNMENT AGREEMENT

**THIS CONFIRMATORY PATENT ASSIGNMENT AGREEMENT** is being entered into by **Sanofi** and **UCB Biopharma SPRL** ("UCB"):

**WHEREAS** the inventions disclosed in the patent applications listed in the Patent Application Schedule attached hereto ("The Inventions" and "The Patent Applications," respectively) were developed pursuant to a joint development agreement between Sanofi and UCB dated March 10, 2014, in effect at the time the inventions were made ("The Agreement"); and

**WHEREAS** The Agreement provided that, for mutual consideration hereby acknowledged, all of Sanofi's and UCB's rights in The Inventions developed pursuant to The Agreement are jointly and equally shared by Sanofi and UCB;


**NOW THEREFORE**, Sanofi and UCB hereby confirm that by virtue of The Agreement, all right, title, and interest in The Inventions and The Patent Applications vested jointly and equally in UCB and Sanofi at the time The Inventions were made and to the extent further required by The Agreement and any applicable law (a) Sanofi assigned to UCB and (b) UCB assigned to Sanofi 50% of its right, title, and interest in The Inventions and The Patent Applications, and any and all letters patent or patents in the United States of America and all foreign countries that may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of The Patent Applications and patent(s) issued therefrom, or reissues, renewals, revivals, reexaminations or extensions of The Patent Applications and patent(s) issued therefrom ("The Patents"), and all rights under all applicable intellectual property treaties and conventions, and the full benefits thereof, and all rights, privileges and advantages appertaining thereto, including any and all rights of each of UCB and Sanofi to damages, profits or recoveries of any nature for past, present and future infringement of The Patents, and the payment of any and all maintenance fees, taxes, and the like, TO HOLD the same unto and to the joint use of UCB and Sanofi, their successors and assigns during the residue of the respective terms for any patent issuing from The Patent Applications were or will be granted and during any such terms, and for any and all rights extending from the divisions, continuations, continuations-in-part, reissues, renewals, revivals, reexaminations and extensions.

**AND** for the same consideration, Sanofi and UCB hereby covenant and agree to and with the other, their successors, legal representatives and assigns that each will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the recordation of this assignment of The Patent Applications and The Inventions.


**AND** Sanofi and UCB hereby request the Commissioner of Patents to issue, jointly to UCB and Sanofi, any and all Letters Patent of the United States arising from such Patents for the use and behalf of UCB and Sanofi, their successors, legal representatives, and assigns.

FOR SANOFI

WITNESS my hand and seal this 21 day of August, 2019.


  
By: Kubel Dominique  
Title: Head of Synthetic Molecules Patents


  
WITNESS Caroline RONANOWSKI  
Patent Attorney


  
WITNESS Fatma Said  
Patent Assistant

FOR UCB BIOPHARMA SPRL

WITNESS my hand and seal this \_\_\_ day of 26 JUN 2019, 2019.

  
By: Stéphane DROUIN  
Title: Proxy and Legal Representative

  
WITNESS Ekimich Marina  
SENIOR PATENT ADMINISTRATOR

  
WITNESS Chantal Bernaerts  
SENIOR TRADEMARK COUNSEL

PATENT APPLICATION SCHEDULE

US Patent Application No.	US Filing Date
15/513,357	22 March 2017
15/736,558	14 December 2017
16/086311	18 September 2018
16/086414	19 September 2018
16/086408	19 September 2018
16/086418	19 September 2018
16/220,847	14 December 2018
16/470,999	19 June 2019